Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
And are there any synergies you would be able to leverage with the non-small cell sales teams when entering those markets?
By June 2023, the two companies had announced that they had started treating their first patient in a phase three trial for non-small cell lung cancer.
Checkpoint sees this as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer as olafertinib is a third-generation epidermal growth factor receptor or EGFR inhibitor.
I’ll begin by discussing adagrasib, starting with first-line non-small cell lung cancer, where we expect to share key updates across our multipronged development approach in the second half of this year.
In the ongoing study, the original three cohorts included patients with non-small cell lung cancer, EGFR wild type, gastric and gastroesophageal junction adenocarcinoma and pancreatic hepatocellular and biliary tract cancers respectively.
Prior to LUNAR, the last phase 3 trial to lead to significant improvement in OS in late-stage, platinum-resistant non-small cell lung cancer was six years ago, underlining the difficulty in treating this disease.
We wanted to ask how do you think about the second-line and third-line colorectal markets for anagrassib in relative size to the non-small cell lung?